In this article, the author discusses the need to build an economic value strategy that addresses the sometimes disparate perspectives of key stakeholders. To read the article, click the link below.
CAR-T vs. bispecific therapies: Two growth stories are reshaping hematologic oncology
While both CAR-T cell therapies and bispecific antibodies have experienced rapid growth in recent years, new analysis by CRA’s Chris Nüesch suggests that the...
